| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6242358 | Respiratory Medicine | 2014 | 7 Pages |
Abstract
This study suggests that significant numbers of omalizumab-naïve severe allergic asthma patients in Germany/Italy are eligible for omalizumab therapy. Despite proven benefits in uncontrolled severe allergic asthma, adjunctive omalizumab therapy is underutilized.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Roland Buhl, Andrea Gili Marco, Daniel Cohen, Giorgio Walter Canonica,